research use only

CFSE Dyes chemical

Name: CFSE
Brand: Selleck Chemicals
SKU: S8269
Availability: InStock
Rating: 5 (21 reviews)

Cat.No.S8269

Carboxyfluorescein succinimidyl ester (CFSE, 5(6)-Carboxyfluorescein diacetate succinimidyl ester, CFDA-SE, 5(6)-CFDA N-succinmidyl ester) is a fluorescent cell staining dye. This compound is frequently used in cell proliferation assay and motility assays. It is cell permeable and covalently couples, via its succinimidyl group, to intracellular molecules, notably, to intracellular lysine residues and other amine sources.

Chemical Structure

Molecular Weight: 557.46

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: Purity: 99.85%

99.85

Related Targets	Others Antineoplastic and Immunosuppressive Antibiotics ADC Cytotoxin PROTAC Selection Antibiotics for Transfected Cell Antibiotics for Mammalian Cell Culture ADC Linker Antibiotics for Plant Cell Culture PROTAC Linker Hydrotropic Agents Antibody-Drug Conjugate E3 ligase Ligand Target Protein Ligand Molecular Glues Enzyme Substrate Drug-Linker Conjugates for ADC Surfactant Chelating Agent
Related Products	Propidium Iodide D-Luciferin D-Luciferin sodium salt Crystal Violet Hematoxylin DFO WST-8 Thiazolyl Blue Dihydroethidium Hoechst 33342 JC-1 Rhodamine B DAPI Dihydrochloride Nile Red Ponceau S MKT-077 Phenol Red Nitrotetrazolium Blue chloride Biocytin R-Phycoerythrin PNPP TMB-PS 2-DI-1-ASP TMRE Oil Red O FM1-43 Pyronin Y Lucigenin Ru(bpy)2(mcbpy-O-Su-ester)(PF6)2 Thioflavine S

Chemical Information, Storage & Stability

Molecular Weight	557.46	Formula	C₂₉H₁₉NO₁₁	Storage (From the date of receipt)	3 years -20°C(in the dark) powder
CAS No.	150347-59-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Carboxyfluorescein succinimidyl ester, 5(6)-Carboxyfluorescein diacetate succinimidyl ester, CFDA-SE, 5(6)-CFDA N-succinmidyl ester			Smiles	CC(=O)OC1=CC=C2C(=C1)OC3=C(C=CC(=C3)OC(C)=O)C24OC(=O)C5=CC(=CC=C45)C(=O)ON6C(=O)CCC6=O.CC(=O)OC7=CC=C8C(=C7)OC9=C(C=CC(=C9)OC(C)=O)C8%10OC(=O)C%11=CC=C(C=C%10%11)C(=O)ON%12C(=O)CCC%12=O

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (179.38 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.500mg/ml (4.48mM)	Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (8.97mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.500mg/ml (4.48mM)	Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.500mg/ml (0.90mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro	Preparation of CFDA-SE working solution 1.1 Preparation of the stock solution Dissolve 1 mg of CFDA-SE in 0.1794 mL of DMSO to obtain 10 mM of CFSE. Note: It is recommended to store the stock solution at -20 ℃ or -80 ℃ away from light and avoid repetitive freeze-thaw cycles. 1.2 Preparation of this compound working solution Dilute the stock solution in serum-free cell culture medium or PBS to obtain 5-10 μM of this chemical working solution. Note: Please adjust the concentration of this compound working solution according to the actual situation. Cell staining 2.1 For suspension cells: Centrifuge at 1000 g at 4℃ for 3-5 minutes and then discard the supernatant. Wash twice with PBS, 5 minutes each time. For adherent cells: Discard the cell culture medium, and add trypsin to dissociate cells to make a single-cell suspension. Centrifuge at 1000 g at 4℃ for 3-5 minutes and then discard the supernatant. Wash twice with PBS, 5 minutes each time. 2.2 Add 1 mL of this compound working solution, and then incubate at room temperature for 30 minutes. 2.3 Centrifuge at 400 g at 4℃ for 3-4 minutes and then discard the supernatant. 2.4 Wash twice with PBS, 5 minutes each time. 2.5 Resuspend cells with serum-free cell culture medium or PBS, and then detect by fluorescence microscope or flow cytometer.
In vivo	In vivo labeling of cells with CFSE is feasible with virtually no toxic effect on the labeled or adjacent cells. It has advantages in relatively long-term migration studies as demonstrated by the recovery of T-cells in the peripheral lymphoid organs^[2].
References	[1] https://pubmed.ncbi.nlm.nih.gov/15944752/ [2] https://pubmed.ncbi.nlm.nih.gov/9570923/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02028403	Completed	HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)	June 2014	Phase 1
NCT01376726	Completed	HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)\|Novartis Vaccines and Diagnostics Inc	July 2011	Phase 1
NCT01029548	Completed	HIV Infections	Barbara Ensoli MD\|Istituto Superiore di Sanità	April 2008	--
NCT01024556	Completed	HIV Infection	Barbara Ensoli MD\|Istituto Superiore di Sanità	March 2008	--

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):